Combination therapies, effectiveness, and adherence in patients with HIV infection: Clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir

HIV/AIDS - Research and Palliative Care

Volumn 5, Issue , 2013, Pages 41-49

  Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Human immunodeficiency virus; Non nucleoside reverse transcriptase inhibitors; Resistance; Rilpivirine; Treatment

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALANINE AMINOTRANSFERASE; ANTACID AGENT; ANTICONVULSIVE AGENT; CHOLESTEROL; DEXAMETHASONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR; EMTRICITABINE; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR; EPLIVERA; GLUTAMIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSINE; MACROLIDE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; RIFAMYCIN DERIVATIVE; RILPIVIRINE; SILDENAFIL; TENOFOVIR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; DIZZINESS; DREAM; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; GRAPEFRUIT; GRAPEFRUIT JUICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MONOTHERAPY; NAUSEA; NIGHTMARE; NONHUMAN; PATIENT COMPLIANCE; QT PROLONGATION; REVIEW; SIDE EFFECT; TABLET FORMULATION; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 84873685857     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/HIV.S32377     Document Type: Review

References (24)

1. Asahchop EL, Wainberg MA, Sloan RD, et al. Antiviral drug resistance and the need for development of new HIV-1reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2012;56:5000-5008.
2. Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr. 2012;60:33-42.
3. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238-246.
4. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011; 378:229-237.
5. Cohen C, Molina JM, Cassetti I, et al. Pooled week 96 efficacy, resistance and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults. Presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17-20, 2011.
6. Cohen C, Molina JM, Cahn P, et al. Pooled week 48 effcacy and safety results from ECHO and THRIVE, two double-blind, randomized, Phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patients. Abstract #TPOI-3 presented at the American Conference for the Treatment of HIV, Denver, Colorado, April 7-9, 2011.
7. Hodder S, Arasteh K, De Wet J, et al. Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13:406-415.
8. MillsA, Cohen C, De Jesus E, et al. Switching from efavirenz-emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) single table regimen (STR) to emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR in virologically suppressed, HIV-1 infected subjects. Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2011.
9. CrauwelsH, Vingerhoets J, Ryan R, et al. Pharmacokinetic parameters of once-daily TMC278 following administration of efavirenz in healthy volunteers. Presented at the 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 27-March, 2011.
10. Nelson M, Amaya G, Clumeck N, et al. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother. 2012;67:2020-2028.
11. Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24:55-65.
12. Wilkin A, Pozniak AL, Morales-Ramirez J, et al. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses. 2012;28:437-446.
13. Das K, Bauman JD, Clark AD Jr, et al. High-resolution structures of HIV-1reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A. 2008;105:1466-1471.
14. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010;54:718-727.
15. Asahchop EL, Oliveira M, Wainberg MA, et al. Characterization of the E138K resistance mutation in HIV-1reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother. 2011;55:600-607.
16. Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr. 2012;59:39-46.
17. Petrella M, Wainberg MA. Might the M184V substitution in HIV-1 RT confer clinical benefit? AIDS Rev. 2002;4:224-232.
18. Xu HT, Asahchop EL, Oliveira M, et al. Compensation by the E138K mutation in HIV-1reverse transcriptase of deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol. 2011;85:11300-11308.
19. Hu Z, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol. 2011;85: 11309-11314.
20. Kulkarni R, Babaoglu K, Lansdon EB, et al. The HIV-1reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J Acquir Immune Defic Syndr. 2012;59:47-54.
21. Edurant™ (prescribing information), Janssen. European Medicines Agency product information. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdf. Accessed January 13, 2013.
22. Edurant™ (prescribing information). Tibotec Pharmaceuticals, full prescribing information label. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf. Accessed January 13, 2013.
23. Cohen C, Green J, Olivet H, et al. A randomized pilot study of tenofovir/emtricitabine (TDF/FTC) boosted atazanavir (ATV/r) vs raltegravir (RAL BID) ATV/r vs RAL BID ATV BID. Presented at the Eleventh International Congress on Drug Therapy in HIV Infection, Glasgow, UK: November 11-15, 2012.
24. Fisher M, Palella F, Tebas P, et al. SPIRIT: switching to emtricitabine/rilpivirine/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV suppression at week 48. Presented at the Eleventh International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 11-15, 2012.